this trial will evaluate the safety and effectiveness of the evoque tricuspid valve replacement system for patients with severe tricuspid regurgitation.
recall that our sales were dramatically impacted in the last few weeks of q1 2020 as procedures fell due to covid disruptions.
i 'd also like to touch on edwards ' response to the pandemic and our efforts to better support our patients , employees and the community.
one year later , after an extraordinarily difficult global crisis , i 'm encouraged by the signs of recovery and although we recognize that many people are still struggling around the world.
as we anniversary our one year impact of the pandemic on our financial results , i 'd like to briefly reflect on the current environment and to discuss our 2021 and longer - term priorities as a company.
our sales growth this quarter was better than expected across all product lines.
although we expect the pandemic will impact the global healthcare system based on the environment as we exited the quarter , we have continued confidence in our positive 2021 outlook.
finally , a quick reminder that when using terms underlying and adjusted , management is referring to non-gaap financial measures , otherwise , they are referring to gaap results.
looking beyond 2021 , we remain confident in our long - term strategy and our pipeline of innovative therapies.
also in tmtt , we initiated the triscend ii us pivotal trial for transcatheter tricuspid replacement.
we continue to believe that 2021 will be an important growth year for edwards with mid-teen sales growth highlighting the importance of treating structural heart patients even during this pandemic.
we also anticipate meaningful progress on expanding large under- appreciated and underserved transcatheter opportunities in 2021.
also earlier this month , we received approval to begin treating patients at low surgical risk in japan with sapien 3.
recently , we achieved several important milestones.
in addition , the first patients were recently treated with our next - generation transcatheter mitral replacement system called evoque eos through the miscend study.
just after the close of regular trading , edwards lifesciences released first quarter 2021 financial results.
